{"title":"前庭神经鞘瘤的质子治疗。","authors":"Gillian A Whitfield, Neil G Burnet","doi":"10.1016/B978-0-12-824534-7.00017-2","DOIUrl":null,"url":null,"abstract":"<p><p>This chapter discusses the treatment of vestibular schwannoma using proton beam therapy (PBT), which has been used in stereotactic radiosurgery, hypofractionated stereotactic radiotherapy, and fully fractionated radiotherapy. Using PBT, almost no dose is delivered beyond the proton Bragg peak, so compared to photon therapy the integral dose is reduced and less dose may be delivered to specific normal tissues, which may, in turn, reduce some acute and/or late toxicities. In PBT, however, there are additional uncertainties, including range uncertainty, which requires a larger \"safety margin\" than is typically required for photon radiosurgery or hypofractionated stereotactic radiotherapy. The few published PBT series that describe patient outcomes are presented, all retrospective single center series, which do not suggest that local control or cranial nerve toxicity is more favorable than with photon therapy. Other toxicities, such as neurocognitive outcomes, risk of stroke, and radiation-induced malignancies, cannot be evaluated from the limited data. However, these series largely reflect now outdated treatment planning and delivery methods and do not include the latest Pencil Beam Scanning technology. It remains to be established whether outcomes with modern state-of-the-art PBT may be more favorable and whether particular subgroups, such as pediatric and young adult patients, may benefit.</p>","PeriodicalId":12907,"journal":{"name":"Handbook of clinical neurology","volume":"212 ","pages":"289-299"},"PeriodicalIF":0.0000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Proton therapy for vestibular schwannomas.\",\"authors\":\"Gillian A Whitfield, Neil G Burnet\",\"doi\":\"10.1016/B978-0-12-824534-7.00017-2\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>This chapter discusses the treatment of vestibular schwannoma using proton beam therapy (PBT), which has been used in stereotactic radiosurgery, hypofractionated stereotactic radiotherapy, and fully fractionated radiotherapy. Using PBT, almost no dose is delivered beyond the proton Bragg peak, so compared to photon therapy the integral dose is reduced and less dose may be delivered to specific normal tissues, which may, in turn, reduce some acute and/or late toxicities. In PBT, however, there are additional uncertainties, including range uncertainty, which requires a larger \\\"safety margin\\\" than is typically required for photon radiosurgery or hypofractionated stereotactic radiotherapy. The few published PBT series that describe patient outcomes are presented, all retrospective single center series, which do not suggest that local control or cranial nerve toxicity is more favorable than with photon therapy. Other toxicities, such as neurocognitive outcomes, risk of stroke, and radiation-induced malignancies, cannot be evaluated from the limited data. However, these series largely reflect now outdated treatment planning and delivery methods and do not include the latest Pencil Beam Scanning technology. It remains to be established whether outcomes with modern state-of-the-art PBT may be more favorable and whether particular subgroups, such as pediatric and young adult patients, may benefit.</p>\",\"PeriodicalId\":12907,\"journal\":{\"name\":\"Handbook of clinical neurology\",\"volume\":\"212 \",\"pages\":\"289-299\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Handbook of clinical neurology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/B978-0-12-824534-7.00017-2\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Handbook of clinical neurology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/B978-0-12-824534-7.00017-2","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
This chapter discusses the treatment of vestibular schwannoma using proton beam therapy (PBT), which has been used in stereotactic radiosurgery, hypofractionated stereotactic radiotherapy, and fully fractionated radiotherapy. Using PBT, almost no dose is delivered beyond the proton Bragg peak, so compared to photon therapy the integral dose is reduced and less dose may be delivered to specific normal tissues, which may, in turn, reduce some acute and/or late toxicities. In PBT, however, there are additional uncertainties, including range uncertainty, which requires a larger "safety margin" than is typically required for photon radiosurgery or hypofractionated stereotactic radiotherapy. The few published PBT series that describe patient outcomes are presented, all retrospective single center series, which do not suggest that local control or cranial nerve toxicity is more favorable than with photon therapy. Other toxicities, such as neurocognitive outcomes, risk of stroke, and radiation-induced malignancies, cannot be evaluated from the limited data. However, these series largely reflect now outdated treatment planning and delivery methods and do not include the latest Pencil Beam Scanning technology. It remains to be established whether outcomes with modern state-of-the-art PBT may be more favorable and whether particular subgroups, such as pediatric and young adult patients, may benefit.
期刊介绍:
The Handbook of Clinical Neurology (HCN) was originally conceived and edited by Pierre Vinken and George Bruyn as a prestigious, multivolume reference work that would cover all the disorders encountered by clinicians and researchers engaged in neurology and allied fields. The first series of the Handbook (Volumes 1-44) was published between 1968 and 1982 and was followed by a second series (Volumes 45-78), guided by the same editors, which concluded in 2002. By that time, the Handbook had come to represent one of the largest scientific works ever published. In 2002, Professors Michael J. Aminoff, François Boller, and Dick F. Swaab took on the responsibility of supervising the third (current) series, the first volumes of which published in 2003. They have designed this series to encompass both clinical neurology and also the basic and clinical neurosciences that are its underpinning. Given the enormity and complexity of the accumulating literature, it is almost impossible to keep abreast of developments in the field, thus providing the raison d''être for the series. The series will thus appeal to clinicians and investigators alike, providing to each an added dimension. Now, more than 140 volumes after it began, the Handbook of Clinical Neurology series has an unparalleled reputation for providing the latest information on fundamental research on the operation of the nervous system in health and disease, comprehensive clinical information on neurological and related disorders, and up-to-date treatment protocols.